Andrew Su1, Jeffrey L Conklin2,3, Alireza Sedarat2. 1. Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 10945 Le Conte Avenue, Suite 2114, Los Angeles, CA, 90095, USA. amsu@mednet.ucla.edu. 2. Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 10945 Le Conte Avenue, Suite 2114, Los Angeles, CA, 90095, USA. 3. Gastrointestinal Motor Function Laboratory, UCLA, Los Angeles, CA, USA.
Abstract
PURPOSE OF REVIEW: Gastroparesis remains a difficult-to-treat disease with limited therapeutic options. Though patients often have a common syndrome of stereotypic symptoms, the underlying pathophysiology is heterogeneous, often leading to variable treatment responses. Due to limitations in medical and surgical therapies, endoscopic options have been increasingly explored. These options can be broadly categorized into pyloric-directed therapy, non-pyloric-directed therapy, and nutritional support. In this review, we will highlight current and emerging endoscopic options, such as gastric per-oral endoscopic myotomy (G-POEM). RECENT FINDINGS: Early retrospective studies on G-POEM offer encouraging results up to one year out, with an acceptable safety profile. Other pyloric-directed therapies, such as pyloric dilation and stenting, have also been explored. While emerging endoscopic therapeutic options are encouraging, efficacy will likely depend on a better characterization of underlying pathophysiology and improved patient selection. Future prospective, controlled studies are needed.
PURPOSE OF REVIEW: Gastroparesis remains a difficult-to-treat disease with limited therapeutic options. Though patients often have a common syndrome of stereotypic symptoms, the underlying pathophysiology is heterogeneous, often leading to variable treatment responses. Due to limitations in medical and surgical therapies, endoscopic options have been increasingly explored. These options can be broadly categorized into pyloric-directed therapy, non-pyloric-directed therapy, and nutritional support. In this review, we will highlight current and emerging endoscopic options, such as gastric per-oral endoscopic myotomy (G-POEM). RECENT FINDINGS: Early retrospective studies on G-POEM offer encouraging results up to one year out, with an acceptable safety profile. Other pyloric-directed therapies, such as pyloric dilation and stenting, have also been explored. While emerging endoscopic therapeutic options are encouraging, efficacy will likely depend on a better characterization of underlying pathophysiology and improved patient selection. Future prospective, controlled studies are needed.
Authors: Dong K Kim; Alexander A Hindenburg; Sushil K Sharma; Chang Ho Suk; Frank G Gress; Harry Staszewski; James H Grendell; William P Reed Journal: Ann Surg Oncol Date: 2005-03-03 Impact factor: 5.344
Authors: Yen-I Chen; Takao Itoi; Todd H Baron; Jose Nieto; Yamile Haito-Chavez; Ian S Grimm; Amr Ismail; Saowanee Ngamruengphong; Majidah Bukhari; Gulara Hajiyeva; Ahmad S Alawad; Vivek Kumbhari; Mouen A Khashab Journal: Surg Endosc Date: 2016-11-10 Impact factor: 4.584
Authors: P Mekaroonkamol; L Y Li; S Dacha; Y Xu; S D Keilin; F F Willingham; Q Cai Journal: Neurogastroenterol Motil Date: 2016-05-15 Impact factor: 3.598
Authors: Pankaj J Pasricha; Katherine P Yates; Irene Sarosiek; Richard W McCallum; Thomas L Abell; Kenneth L Koch; Linda Anh B Nguyen; William J Snape; William L Hasler; John O Clarke; Sameer Dhalla; Ellen M Stein; Linda A Lee; Laura A Miriel; Mark L Van Natta; Madhusudan Grover; Gianrico Farrugia; James Tonascia; Frank A Hamilton; Henry P Parkman Journal: Gastroenterology Date: 2017-10-28 Impact factor: 22.682
Authors: Matthias C Schrempf; David R M Pinto; Sebastian Wolf; Bernd Geissler; Florian Sommer; Michael Hoffmann; Dmytro Vlasenko; Johanna Gutschon; Matthias Anthuber Journal: Trials Date: 2022-01-25 Impact factor: 2.279